Haemonetics Co. (NYSE:HAE – Get Free Report) has earned a consensus rating of “Moderate Buy” from the four brokerages that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $109.50.
A number of equities analysts have issued reports on HAE shares. Needham & Company LLC upgraded shares of Haemonetics from a “hold” rating to a “buy” rating and set a $112.00 price objective on the stock in a research report on Wednesday, June 12th. JMP Securities boosted their price objective on shares of Haemonetics from $115.00 to $125.00 and gave the company a “market outperform” rating in a research report on Friday, May 10th. Finally, Barrington Research boosted their price objective on shares of Haemonetics from $105.00 to $107.00 and gave the company an “outperform” rating in a research report on Friday, May 10th.
View Our Latest Analysis on HAE
Insider Activity
Institutional Investors Weigh In On Haemonetics
A number of hedge funds and other institutional investors have recently bought and sold shares of HAE. SG Americas Securities LLC purchased a new stake in Haemonetics in the fourth quarter worth about $345,000. Pacer Advisors Inc. grew its holdings in shares of Haemonetics by 64.8% during the fourth quarter. Pacer Advisors Inc. now owns 9,098 shares of the medical instruments supplier’s stock valued at $778,000 after buying an additional 3,579 shares during the last quarter. LVZ Inc. grew its holdings in shares of Haemonetics by 9.4% during the fourth quarter. LVZ Inc. now owns 3,006 shares of the medical instruments supplier’s stock valued at $257,000 after buying an additional 259 shares during the last quarter. ABLE Financial Group LLC grew its holdings in shares of Haemonetics by 28.4% during the fourth quarter. ABLE Financial Group LLC now owns 7,251 shares of the medical instruments supplier’s stock valued at $620,000 after buying an additional 1,606 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Haemonetics by 3.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 22,874 shares of the medical instruments supplier’s stock valued at $1,956,000 after buying an additional 838 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.
Haemonetics Price Performance
Shares of NYSE:HAE opened at $91.06 on Wednesday. The stock has a market cap of $4.64 billion, a PE ratio of 39.76, a PEG ratio of 1.66 and a beta of 0.29. The company’s fifty day moving average is $87.07 and its 200 day moving average is $83.95. Haemonetics has a 52 week low of $70.74 and a 52 week high of $97.97. The company has a quick ratio of 1.50, a current ratio of 2.56 and a debt-to-equity ratio of 0.83.
Haemonetics (NYSE:HAE – Get Free Report) last issued its earnings results on Thursday, May 9th. The medical instruments supplier reported $0.90 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.02. The company had revenue of $343.00 million for the quarter, compared to analysts’ expectations of $329.53 million. Haemonetics had a net margin of 8.98% and a return on equity of 22.25%. The firm’s revenue was up 12.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.77 EPS. Research analysts anticipate that Haemonetics will post 4.57 earnings per share for the current year.
About Haemonetics
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.
See Also
- Five stocks we like better than Haemonetics
- Stock Sentiment Analysis: How it Works
- Is Crypto Cool Again? What Stocks You Should Be Watching
- What is the S&P/TSX Index?
- Why Call Options Volume for These 2 Stocks Spiked Together
- What is Short Interest? How to Use It
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.